Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | TGTX |
---|---|---|
09:32 ET | 20048 | 17.59 |
09:34 ET | 7656 | 17.73 |
09:36 ET | 64957 | 17.93 |
09:38 ET | 14890 | 18.1599 |
09:39 ET | 34276 | 18.375 |
09:41 ET | 33401 | 18.43 |
09:43 ET | 42448 | 18.39 |
09:45 ET | 12952 | 18.33 |
09:48 ET | 19899 | 18.27 |
09:50 ET | 5983 | 18.33 |
09:52 ET | 5488 | 18.31 |
09:54 ET | 10998 | 18.35 |
09:56 ET | 13978 | 18.4 |
09:57 ET | 720 | 18.3723 |
09:59 ET | 3742 | 18.42 |
10:01 ET | 26219 | 18.481 |
10:03 ET | 4405 | 18.38 |
10:06 ET | 1293 | 18.375 |
10:08 ET | 11536 | 18.4801 |
10:10 ET | 36944 | 18.56 |
10:12 ET | 10509 | 18.375 |
10:14 ET | 15178 | 18.41 |
10:15 ET | 11145 | 18.46 |
10:17 ET | 2826 | 18.42 |
10:19 ET | 5414 | 18.43 |
10:21 ET | 2851 | 18.435 |
10:24 ET | 8155 | 18.51 |
10:26 ET | 7575 | 18.5 |
10:28 ET | 1485 | 18.52 |
10:30 ET | 8462 | 18.53 |
10:32 ET | 1325 | 18.495 |
10:33 ET | 6584 | 18.52 |
10:35 ET | 10603 | 18.54 |
10:37 ET | 2038 | 18.52 |
10:39 ET | 4424 | 18.52 |
10:42 ET | 7217 | 18.48 |
10:44 ET | 8140 | 18.5407 |
10:46 ET | 5066 | 18.51 |
10:48 ET | 26436 | 18.62 |
10:50 ET | 10070 | 18.56 |
10:51 ET | 7675 | 18.63 |
10:53 ET | 25603 | 18.7127 |
10:55 ET | 10309 | 18.72 |
10:57 ET | 15574 | 18.79 |
11:00 ET | 18354 | 18.86 |
11:02 ET | 11836 | 18.855 |
11:04 ET | 8923 | 18.82 |
11:06 ET | 13787 | 18.8 |
11:08 ET | 11323 | 18.805 |
11:09 ET | 14001 | 18.88 |
11:11 ET | 13127 | 18.86 |
11:13 ET | 8866 | 18.85 |
11:15 ET | 8281 | 18.81 |
11:18 ET | 2856 | 18.86 |
11:20 ET | 8057 | 18.82 |
11:22 ET | 10673 | 18.8278 |
11:24 ET | 2910 | 18.795 |
11:26 ET | 4738 | 18.795 |
11:27 ET | 5646 | 18.7895 |
11:29 ET | 3022 | 18.8 |
11:31 ET | 7531 | 18.7128 |
11:33 ET | 3888 | 18.6553 |
11:36 ET | 16715 | 18.61 |
11:38 ET | 3613 | 18.58 |
11:40 ET | 8324 | 18.5537 |
11:42 ET | 7874 | 18.57 |
11:44 ET | 1700 | 18.58 |
11:45 ET | 10526 | 18.5105 |
11:47 ET | 3287 | 18.52 |
11:49 ET | 5047 | 18.55 |
11:51 ET | 1616 | 18.55 |
11:54 ET | 2502 | 18.55 |
11:56 ET | 6557 | 18.6 |
11:58 ET | 13055 | 18.54 |
12:00 ET | 2618 | 18.55 |
12:02 ET | 540 | 18.5 |
12:03 ET | 7161 | 18.5 |
12:05 ET | 1753 | 18.535 |
12:07 ET | 3950 | 18.46 |
12:09 ET | 9089 | 18.48 |
12:12 ET | 1700 | 18.53 |
12:14 ET | 1634 | 18.45 |
12:16 ET | 6800 | 18.45 |
12:18 ET | 1568 | 18.45 |
12:20 ET | 3052 | 18.43 |
12:21 ET | 2679 | 18.4699 |
12:23 ET | 1012 | 18.45 |
12:25 ET | 2457 | 18.45 |
12:27 ET | 4470 | 18.43 |
12:30 ET | 2410 | 18.43 |
12:32 ET | 6403 | 18.38 |
12:34 ET | 2495 | 18.37 |
12:36 ET | 6043 | 18.4 |
12:38 ET | 818 | 18.41 |
12:39 ET | 4466 | 18.39 |
12:41 ET | 3062 | 18.44 |
12:43 ET | 2012 | 18.44 |
12:45 ET | 619 | 18.45 |
12:48 ET | 1435 | 18.43 |
12:50 ET | 1783 | 18.41 |
12:52 ET | 9526 | 18.41 |
12:54 ET | 1243 | 18.39 |
12:56 ET | 1465 | 18.39 |
12:57 ET | 4021 | 18.395 |
12:59 ET | 6421 | 18.405 |
01:01 ET | 3632 | 18.37 |
01:03 ET | 2300 | 18.38 |
01:06 ET | 100 | 18.37 |
01:08 ET | 1397 | 18.37 |
01:10 ET | 200 | 18.37 |
01:12 ET | 2132 | 18.38 |
01:14 ET | 2741 | 18.37 |
01:15 ET | 3317 | 18.31 |
01:17 ET | 1553 | 18.3 |
01:19 ET | 8017 | 18.32 |
01:21 ET | 833 | 18.3 |
01:24 ET | 1485 | 18.28 |
01:26 ET | 1911 | 18.27 |
01:28 ET | 722 | 18.25 |
01:30 ET | 1620 | 18.275 |
01:32 ET | 2001 | 18.27 |
01:33 ET | 568 | 18.26 |
01:35 ET | 1753 | 18.2464 |
01:37 ET | 100 | 18.245 |
01:39 ET | 2706 | 18.26 |
01:42 ET | 7631 | 18.2 |
01:44 ET | 13288 | 18.19 |
01:46 ET | 3251 | 18.22 |
01:48 ET | 5694 | 18.19 |
01:50 ET | 300 | 18.21 |
01:51 ET | 16182 | 18.17 |
01:53 ET | 400 | 18.18 |
01:55 ET | 3030 | 18.155 |
01:57 ET | 3023 | 18.17 |
02:00 ET | 3245 | 18.23 |
02:02 ET | 9021 | 18.31 |
02:04 ET | 2120 | 18.315 |
02:06 ET | 800 | 18.34 |
02:08 ET | 2007 | 18.35 |
02:11 ET | 3136 | 18.36 |
02:13 ET | 10166 | 18.35 |
02:15 ET | 4297 | 18.34 |
02:18 ET | 3344 | 18.34 |
02:20 ET | 1650 | 18.33 |
02:22 ET | 1700 | 18.34 |
02:24 ET | 1504 | 18.3155 |
02:26 ET | 4048 | 18.3 |
02:27 ET | 1449 | 18.26 |
02:29 ET | 1533 | 18.28 |
02:31 ET | 4006 | 18.285 |
02:33 ET | 3650 | 18.3198 |
02:36 ET | 1092 | 18.32 |
02:38 ET | 1288 | 18.35 |
02:40 ET | 5800 | 18.365 |
02:42 ET | 2797 | 18.375 |
02:44 ET | 1677 | 18.39 |
02:45 ET | 3120 | 18.361 |
02:47 ET | 1979 | 18.345 |
02:49 ET | 600 | 18.33 |
02:51 ET | 3600 | 18.35 |
02:54 ET | 12938 | 18.32 |
02:56 ET | 2133 | 18.29 |
02:58 ET | 6410 | 18.29 |
03:00 ET | 1700 | 18.3 |
03:02 ET | 3551 | 18.23 |
03:03 ET | 9954 | 18.24 |
03:05 ET | 3356 | 18.26 |
03:07 ET | 8936 | 18.27 |
03:09 ET | 8367 | 18.295 |
03:12 ET | 10275 | 18.295 |
03:14 ET | 1541 | 18.31 |
03:16 ET | 10003 | 18.305 |
03:18 ET | 5842 | 18.3 |
03:20 ET | 2239 | 18.275 |
03:21 ET | 2314 | 18.27 |
03:23 ET | 1962 | 18.255 |
03:25 ET | 9116 | 18.26 |
03:27 ET | 5362 | 18.245 |
03:30 ET | 2090 | 18.255 |
03:32 ET | 3696 | 18.245 |
03:34 ET | 10856 | 18.295 |
03:36 ET | 3611 | 18.309 |
03:38 ET | 4023 | 18.285 |
03:39 ET | 3240 | 18.28 |
03:41 ET | 9760 | 18.25 |
03:43 ET | 6981 | 18.235 |
03:45 ET | 21364 | 18.2 |
03:48 ET | 3989 | 18.19 |
03:50 ET | 8221 | 18.195 |
03:52 ET | 14121 | 18.205 |
03:54 ET | 35479 | 18.175 |
03:56 ET | 40367 | 18.17 |
03:57 ET | 36642 | 18.14 |
03:59 ET | 109886 | 18.15 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
TG Therapeutics Inc | 2.8B | 82.3x | --- |
Twist Bioscience Corp | 2.8B | -14.6x | --- |
ADMA Biologics Inc | 2.7B | -566.2x | --- |
MorphoSys AG | 2.7B | -5.4x | --- |
Arrowhead Pharmaceuticals Inc | 3.2B | -6.1x | --- |
Vericel Corp | 2.2B | 4,710.3x | --- |
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates include Ublituximab (anti-CD20 mAb), TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It is the therapy to target both CD19, a B-cell specific market expressed across B-cell malignancies, and CD47. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.8B |
---|---|
Revenue (TTM) | $289.3M |
Shares Outstanding | 154.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.23 |
EPS | $0.22 |
Book Value | $1.06 |
P/E Ratio | 82.3x |
Price/Sales (TTM) | 9.7 |
Price/Cash Flow (TTM) | 67.8x |
Operating Margin | 16.71% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.